The U.S. Food and Drug Administration has approved Glucovance (glyburide and metformin tablets) by Bristol-Myers Squibb for the treatment of type 2 diabetes.
Glucovance is indicated for use in initial type 2 diabetes therapy, along with diet and exercise, and also as second-line therapy in patients with type 2 diabetes who are currently taking either Glucophage (metformin) or a sulfonylurea and following a regimen of diet and exercise, but whose blood sugar levels are inadequately controlled.
Glucovance combines glyburide and Glucophage, which are two of the most widely prescribed oral medications for diabetes, in a single pill.
Glucovance will be available in three dosing strengths: 1.25 mg/250 mg (glyburide/metformin) tablets, 2.5 mg/500 mg tablets and 5 mg/500 mg tablets.
No comments:
Post a Comment